Denali Therapeutics (DNLI) vs. Its Competitors Head to Head Survey

Denali Therapeutics (NASDAQ:DNLI) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Denali Therapeutics to similar businesses based on the strength of its analyst recommendations, valuation, risk, earnings, dividends, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of current recommendations for Denali Therapeutics and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1	2	13	0	2.75
Denali Therapeutics Competitors	9782	15053	45298	1571	2.54

Denali Therapeutics presently has a consensus target price of $35.85, indicating a potential upside of 84.30%. As a group, “Biotechnology” companies have a potential upside of 97.59%. Given Denali Therapeutics’ competitors higher possible upside, analysts clearly believe Denali Therapeutics has less favorable growth aspects than its competitors.

Insider & Institutional Ownership

92.9% of Denali Therapeutics shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 9.7% of Denali Therapeutics shares are held by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Denali Therapeutics and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Denali Therapeutics	$330.53 million	-$512.54 million	-6.85
Denali Therapeutics Competitors	$691.13 million	$10.43 million	-10.02

Denali Therapeutics’ competitors have higher revenue and earnings than Denali Therapeutics. Denali Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Denali Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-55.27%	-44.24%
Denali Therapeutics Competitors	-9,046.59%	-199.78%	-30.61%

Volatility and Risk

Denali Therapeutics has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Comparatively, Denali Therapeutics’ competitors have a beta of 1.14, indicating that their average share price is 14% more volatile than the S&P 500.

Summary

Denali Therapeutics competitors beat Denali Therapeutics on 7 of the 12 factors compared.

About Denali Therapeutics

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson’s disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.